Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update

[Farooqji]

Despite the COVID-19 pandemic, there has been considerable activity in the clinical development of novel and improved drug-based therapies for the neurodegenerative condition of Parkinson’s disease (PD) during 2020. The agents that were investigated can be divided into “symptomatic” (alleviating the features of the condition) and “disease modifying” (attempting to address the underlying biology of PD) treatments, ST and DMT respectively, with further categorisation possible based on mechanism of action and class of therapy.

content.iospress.com/articl...

[Bolt_Upright]

Thanks Farooqji

Here is a link to the master list of treatments being trialed:

content.iospress.com/downlo...

[jeffreyn]

There is also a PNT article about the document.

Clinical Trials of Parkinson’s Therapies Robust Despite COVID-19

parkinsonsnewstoday.com/202...

[sharoncrayn]

Far more relevant to analyze the Phase III trials and their results.